Meinong Biotech announced that revenue for the first half of 2026 was 328 million yuan, up 38.71% year on year; net profit attributable to shareholders of listed companies was 18.061 million yuan, down 23.23% year on year, and 23.527 million yuan in the first half of 2025; net profit after deducting non-recurring profit and loss was 177.649 million yuan, down 18.66% year on year. As of June 2026, the company has transferred all remaining funds raised to permanently supplement working capital, and completed the relevant special fund raising account procedures.

Meinong Biotech announced that revenue for the first half of 2026 was 328 million yuan, up 38.71% year on year; net profit attributable to shareholders of listed companies was 18.061 million yuan, down 23.23% year on year, and 23.527 million yuan in the first half of 2025; net profit after deducting non-recurring profit and loss was 177.649 million yuan, down 18.66% year on year. As of June 2026, the company has transferred all remaining funds raised to permanently supplement working capital, and completed the relevant special fund raising account procedures.